Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Qgen - You Need To See This

3 Medical Stocks Smart Investors Want

The medical industry, pivotal in elevating the quality of human life, is poised to remain buoyed due to medical breakthroughs, advanced medical discoveries, and rising health consciousness among individuals. Given this backdrop, quality medical stocks McKesson Corporation (MCK), Qiagen N.V. (QGEN), and DaVita Inc. (DVA) could be solid portfolio additions…

3 Medical Research Stocks to Buy This Week

3 Medical Research Stocks to Buy This Week

With the increased demand for innovative medical products and services, the medical research industry is poised for robust growth. Therefore, three medical research stocks Laboratory Corporation of America (LH), Qiagen N.V. (QGEN), and Lantheus Holdings (LNTH) could be solid buys for this week. Keep reading….

3 Medical Stocks Rated BUY

3 Medical Stocks Rated BUY

The healthcare industry is expected to witness robust growth driven by steady demand and increasing technological investments. Moreover, as the industry has traditionally been regarded as recession-proof, quality medical stocks Agilent Technologies (A), Qiagen (QGEN), and Harvard Bioscience (HBIO) may be worth buying now. These stocks are Buy-rated in our…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

5 Safe and Cheap Stocks to Buy Amid the Market Volatility

Amid the heightened volatility in the market on concerns over rising inflation and a potential recession, we think fundamentally sound stocks Anthem (ANTM), Qiagen (QGEN), Bayer Aktiengesellschaft (BAYRY), Amdocs (DOX), and McKesson (MCK), which are currently trading at significant discounts to their peers, could be wise investments now. In addition…

Natera Clocks 28% Jump In Q1 Sales, Lifts FY22 Guidance

Natera Inc (NASDAQ:NTRA) generated Q1 revenues of $194.1 million, up 27.5% Y/Y, beating the consensus of $176.60 million. Product revenues were $190.0 million, an increase of 57.8%. The company processed approximately 489,300 tests, compared to approximately 348,200 tests in Q1 FY21. The gross profit margin compressed to 46.8% from 56.1%, primarily due…

Qiagen Posts Upbeat Q1 Earnings, Raises FY22 Outlook

Qiagen N.V. (NYSE:QGEN) clocked Q1 FY22 revenues of $628.4 million, +11% Y/Y, ahead of the outlook for at least 7% CER growth and well above the consensus of $517.8 million. At constant exchange rates (CER), Q1 revenues jumped 15% Y/Y. Sales were driven by 14% CER growth in the non-COVID-19 product portfolio…

Trading Near 52-Week Lows: Grab These 5 Undervalued Healthcare Stocks Now

Despite possessing solid long-term growth prospects on the back of rising demand from an aging population, many healthcare stocks have been hard hit by the broader market sell-offs over the past couple of months. But given the near-inelastic demand for healthcare solutions and the industry’s long-term growth prospects, we think…

inkl

Read news from The Economist, FT, and more,
with one subscription

Illumina vs. Qiagen: Which Diagnostics & Research Stock is a Better Buy?

Illumina vs. Qiagen: Which Diagnostics & Research Stock is a Better Buy?

The diagnostics and research industry has grown substantially over the past few years with the integration of advanced technologies and impressive breakthroughs in the early diagnosis of chronic diseases. Given the growing investments in this industry, prominent companies Illumina (ILMN) and Qiagen (QGEN) are well-positioned to benefit. Let’s find out…

Death Cross Looms Over Qiagen Investors

Death Cross Looms Over Qiagen Investors

If history is any guide, there may be trouble ahead for shares of Qiagen (NYSE:QGEN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Qiagen Q4 Earnings Beat Expectations On High Demand For COVID-19 Tests, Issues FY22 Guidance

Qiagen Q4 Earnings Beat Expectations On High Demand For COVID-19 Tests, Issues FY22 Guidance

Qiagen N.V. (NYSE: QGEN)

Qiagen: Q4 Earnings Insights

Qiagen: Q4 Earnings Insights

Qiagen (NYSE:QGEN) reported its Q4 earnings results on Tuesday, February 8, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Qiagen beat estimated earnings by 39.62%, reporting an EPS of $0.74 versus an estimate of $0.53.

Qiagen's Earnings: A Preview

Qiagen's Earnings: A Preview

Qiagen (NYSE:QGEN) is set to give its latest quarterly earnings report on Tuesday, 2022-02-08. Here's what investors need to know before the announcement. Analysts estimate that Qiagen will likely report an Earnings Per Share (EPS) of $0.53.

1

Organisations

McKesson Corporation

Bayer Aktiengesellschaft

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

365,217 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play